Four-year trends in Helicobacter pylori IgG serology following successful eradication

被引:50
作者
Cutler, AF
Prasad, VM
Santogade, P
机构
[1] Sinai Hosp, Gastroenterol Sect, Dept Med, Detroit, MI 48235 USA
[2] Henry Ford Hosp, Dept Gastroenterol, Div Internal Med, Detroit, MI 48202 USA
关键词
D O I
10.1016/S0002-9343(98)00134-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Detection of anti-Helicobacter-pylori antibodies is accurate in the diagnosis of the infection, and there is a decline in IgG titers after successful eradication. It is not known whether these titers continue to decline during the next 3 to 4 years. PATIENTS AND METHODS: Patients had been successfully treated for H pylori with triple therapy (metronidazole, tetracycline, and bismuth subsalicylate) during 1990 and 1991. Those who had frozen serum samples available from that time were contacted to have follow-up serum collected in 1994. A simultaneous [C-13]urea breath test was done to confirm H pylori infection status. Serology was determined by quantitative enzyme-linked immunosorbent assay (ELISA) and qualitative immunoassay. RESULTS: All 29 patients who agreed to participate were free of H pylori infection. The-ii had a mean decrease in H pylori IgG titers of 51% from baseline (P <0.001). Titers remained stable from 1 year to a mean of 3.5 years after therapy (range 2.5 to 4.4). Of the 29 patients, 21 (72%) remained seropositive by ELISA 3.5 years after successful H pylori treatment, and 18 (62%) remained positive by rapid serum immunoassay. CONCLUSION: IgG titers against N pylori plateau at a 50% decrease after therapy. Helicobacter pylori serology, either quantitative or qualitative, will yield false positive results in patients who have previously been treated for H pylori and should not be used to determine infection status in this population. (C) 1998 by Excerpta Medica, Inc.
引用
收藏
页码:18 / 20
页数:3
相关论文
共 27 条
[1]  
BARTHEL JS, 1990, REV INFECT DIS, V12, pS107
[2]  
BLOMQUIST C, 1994, AM J GASTROENTEROL, V89, pA200
[3]  
CHODOS JE, 1988, AM J GASTROENTEROL, V83, P1226
[4]   EVALUATION OF A COMMERCIAL ELISA FOR SERODIAGNOSIS OF HELICOBACTER-PYLORI INFECTION [J].
CRABTREE, JE ;
SHALLCROSS, TM ;
HEATLEY, RV ;
WYATT, JI .
JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (04) :326-328
[5]   ROLE OF HELICOBACTER-PYLORI SEROLOGY IN EVALUATING TREATMENT SUCCESS [J].
CUTLER, A ;
SCHUBERT, A ;
SCHUBERT, T .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (12) :2262-2266
[6]  
Cutler AF, 1996, AM J GASTROENTEROL, V91, P85
[7]   ACCURACY OF INVASIVE AND NONINVASIVE TESTS TO DIAGNOSE HELICOBACTER-PYLORI INFECTION [J].
CUTLER, AF ;
HAVSTAD, S ;
MA, CK ;
BLASER, MJ ;
PEREZPEREZ, GI ;
SCHUBERT, TT .
GASTROENTEROLOGY, 1995, 109 (01) :136-141
[8]   EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL-ULCER - A RANDOMIZED, CONTROLLED-STUDY [J].
GRAHAM, DY ;
LEW, GM ;
KLEIN, PD ;
EVANS, DG ;
EVANS, DJ ;
SAEED, ZA ;
MALATY, HM .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (09) :705-708
[9]   TREATMENT OF HELICOBACTER-PYLORI REDUCES THE RATE OF REBLEEDING IN PEPTIC-ULCER DISEASE [J].
GRAHAM, DY ;
HEPPS, KS ;
RAMIREZ, FC ;
LEW, GM ;
SAEED, ZA .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (11) :939-942
[10]   EFFECT OF RANITIDINE AND AMOXICILLIN PLUS METRONIDAZOLE ON THE ERADICATION OF HELICOBACTER-PYLORI AND THE RECURRENCE OF DUODENAL-ULCER [J].
HENTSCHEL, E ;
BRANDSTATTER, G ;
DRAGOSICS, B ;
HIRSCHL, AM ;
NEMEC, H ;
SCHUTZE, K ;
TAUFER, M ;
WURZER, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (05) :308-312